Tradestie Institutional Equity Comparison Engine

SRZN vs IBO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Options & Structure while IBO counters with relative strength in Valuation, Momentum & Technical. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
SRZN N/M vs IBO N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs -12621.0% ยท YoY +408.6% vs +16.7%
Momentum & Technical Winner IBO
1Y +166.7% vs +862.8% ยท 52W Pos 79% vs 67%
Options & Structure Winner SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
1M Return +37.88%
1Y Return +166.67%
Forward P/E N/M
Unified AI Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
1M Return +83.21%
1Y Return +862.75%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +166.67% IBO +862.75% Spread: +696.08 pp (IBO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue IBO Revenue SRZN Op. Margin IBO Op. Margin Margin Edge
FY2022 $10M $0M -354.7% -6808.0% SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M $0M -1210.6% -13381.2% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (5) vs IBO (4)
Institutional Metric SRZN IBO Criterion Row Winner
Market Capitalization Scale $602.5M $44.4M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +16.7% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% -12621.0% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency -62.8% 71.2% Higher ROE IBO
52-Week Range Position Momentum 79% ($12โ€“$38) 67% ($0โ€“$7) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.21ฮฒ ยท 62% Vol -6.72ฮฒ ยท 120% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 32.8 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite IBO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs IBO Buy Guide
SRZN CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.